That LSCs can effectively be eliminated by targeting TIM-3 is supported by in vivo experiments in human AML xenograft mice using the anti-human TIM-3 mouse antibody named ATIK2a. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.